行情

NVRO

NVRO

Nevro
NYSE

实时行情|Nasdaq Last Sale

123.78
-0.42
-0.34%
盘后: 123.78 0 0.00% 16:06 09/21 EDT
开盘
124.68
昨收
124.20
最高
126.36
最低
123.42
成交量
34.00万
成交额
--
52周最高
188.14
52周最低
99.54
市值
43.10亿
市盈率(TTM)
-62.7144
分时
5日
1月
3月
1年
5年
尽管受到 COVID-19 的影响,但 Baxter 和 Medtronic 仍是美国银行 MedTech 的最爱
Noting signs of weaker procedure volumes in Q3 2021 revealed at a recent healthcare conference, Bank of America urges investors to ignore the COVID-19 impact and make investment decisions on MedTech stocks
Seekingalpha · 09/13 17:55
Alger Weatherbie Specialized Growth Portfolio 收购 Apria Inc、Latham Group Inc、Ollie's Bargain ...
GuruFocus News · 09/07 23:38
为什么 Nevro (NVRO) 自上次收益报告以来上涨了 8.6%?
Zacks.com · 09/03 15:31
Nevro 将出席贝尔德 2021 年全球医疗保健会议
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at the Baird 2021 ...
PR Newswire · 08/26 10:00
Nevro 将出席摩根士丹利第 19 届年度全球医疗保健会议
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at the Morgan Stan...
PR Newswire · 08/25 10:00
Bridger Management, Llc 收购 Centene Corp、Nevro Corp、Post Holdings Partnering Corp,出售 HCA ...
GuruFocus News · 08/24 18:38
Nevro 将出席富国银行虚拟医疗会议
/PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. , Nevro's Chairman, CEO and President, will present at the Wells Far...
PR Newswire - PRF · 08/23 10:00
调查 Nevro 的资本使用回报率
After pulling data from Benzinga Pro it seems like during Q2, Nevro's (NYSE:NVRO) reported sales totaled $102.33 million. Despite a 29.98% in earnings, the company posted a loss of $15.76 million.
Benzinga · 08/20 18:02
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解NVRO最新的财务预测,通过NVRO每股收益,每股净资产,每股现金流等数据分析Nevro近期的经营情况,然后做出明智的投资选择。
分析师评级

16位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测NVRO价格均价为138.15,最高价位165.00,最低价为112.00。
EPS
机构持股
总机构数: 294
机构持股: 4,468.38万
持股比例: 128.16%
总股本: 3,486.57万
类型机构数股数
增持
74
247.33万
建仓
39
95.41万
减持
62
140.87万
平仓
35
102.76万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
医疗设备、用品及经销
+0.10%
医疗设备和用品
+0.22%
高管信息
Chairman/President/Chief Executive Officer/Director
D. Keith Grossman
Chief Financial Officer
Roderick MacLeod
Chief Human Resource Officer
Lori Ciano
Vice President
Christopher Christoforou
Vice President
Donald Middlebrook
General Counsel/Secretary
Kashif Rashid
Other
David Caraway
Other
Niamh Pellegrini
Lead Director/Independent Director
Michael DeMane
Director
Sridhar Kosaraju
Independent Director
Frank Fischer
Independent Director
Shawn McCormick
Independent Director
Kevin O'Boyle
Independent Director
Karen Prange
Independent Director
Susan Siegel
Independent Director
Brad Vale
Independent Director
Elizabeth Weatherman
暂无数据
NVRO 简况
Nevro Corp.是一家医疗设备公司。该公司开发治疗慢性疼痛的神经调节平台,并将其商业化。该公司的Senza系统是提供HF10疗法的骨髓刺激系统。HF10疗法旨在提供治疗慢性疼痛的神经调节解决方案。HF10疗法缓解背部疼痛及腿部疼痛,在缓解疼痛的同时不造成知觉异常。该疗法对患者、医生及医院有益。Senza可以创造2赫兹到10千赫的电脉冲(包括HF10疗法)。HF10疗法输出10千赫脉搏率的电波。其程序设计算法经数据及临床验证。Senza由引线、试验刺激仪、植入式起搏器、手术工具、临床便携式编程设备、患者远程控制器及移动电源组成。

微牛提供Nevro Corp(NYSE-NVRO)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的NVRO股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易NVRO股票基本功能。